ForPatients
*by Roche*

Chronic Lymphocytic Leukemia

# A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

| Trial Status | Trial Runs In | Trial Identifier |
|---|---|---|
| Terminated | 5 Countries | NCT02336048 2014-004594-16 BO29448 |

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

## *Trial Summary:*

This multicenter, double-blind, randomized, placebo-controlled study will evaluate the safety of a single infusion of tocilizumab versus placebo, administered in addition to standard premedications (antipyretic, antihistamine, and corticosteroid) prior to the first infusion of obinutuzumab administered in combination with oral chlorambucil to participants with previously untreated B-CLL who have comorbidities. All eligible participants will be treated with a total of 6 cycles of obinutuzumab + chlorambucil (cycle length = 28 days).

| Hoffmann-La Roche | Phase 1 |
|---|---|
| Sponsor | Phase |

**NCT02336048 2014-004594-16 BO29448**
Trial Identifiers

## *Eligibility Criteria:*

| Gender | Age | Healthy Volunteers |
|---|---|---|
| All | >= 18 Years | No |